Christopher A Bristow
Overview
Explore the profile of Christopher A Bristow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
5155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thatikonda V, Lyu H, Jurado S, Kostyrko K, Bristow C, Albrecht C, et al.
Nat Cancer
. 2024 Aug;
5(9):1352-1370.
PMID: 39103541
Combination approaches are needed to strengthen and extend the clinical response to KRAS inhibitors (KRASi). Here, we assessed the antitumor responses of KRAS mutant lung and colorectal cancer models to...
2.
Dilly J, Hoffman M, Abbassi L, Li Z, Paradiso F, Parent B, et al.
Cancer Discov
. 2024 Jul;
14(11):2135-2161.
PMID: 38975874
KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS, and...
3.
Pilie P, Giuliani V, Wang W, McGrail D, Bristow C, Ngoi N, et al.
Clin Cancer Res
. 2024 Feb;
30(10):2121-2139.
PMID: 38416404
Purpose: Mutations in the ATM gene are common in multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement of ATM loss of function (LOF)...
4.
Perelli L, Carbone F, Zhang L, Huang J, Le C, Khan H, et al.
Nat Cancer
. 2023 Jun;
4(7):984-1000.
PMID: 37365326
Molecular routes to metastatic dissemination are critical determinants of aggressive cancers. Through in vivo CRISPR-Cas9 genome editing, we generated somatic mosaic genetically engineered models that faithfully recapitulate metastatic renal tumors....
5.
Thatikonda V, Lu H, Jurado S, Kostyrko K, Bristow C, Bosch K, et al.
bioRxiv
. 2023 Feb;
PMID: 36747713
Efforts to improve the anti-tumor response to KRAS targeted therapy have benefited from leveraging combination approaches. Here, we compare the anti-tumor response induced by the SOS1-KRAS interaction inhibitor, BI-3406, combined...
6.
Yap T, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, et al.
Nat Med
. 2023 Jan;
29(1):115-126.
PMID: 36658425
Although targeting oxidative phosphorylation (OXPHOS) is a rational anticancer strategy, clinical benefit with OXPHOS inhibitors has yet to be achieved. Here we advanced IACS-010759, a highly potent and selective small-molecule...
7.
Class C, Lukan C, Bristow C, Do K
Bioinformatics
. 2022 Nov;
39(1).
PMID: 36440915
Summary: The NanoTube is an open-source pipeline that simplifies the processing, quality control, normalization and analysis of NanoString nCounter gene expression data. It is implemented in an extensible R library,...
8.
Novak L, Chou J, Colic M, Bristow C, Hart T
Nucleic Acids Res
. 2022 Nov;
51(D1):D1117-D1121.
PMID: 36350677
PICKLES (https://pickles.hart-lab.org) is an updated web interface to a freely available database of genome-scale CRISPR knockout fitness screens in human cell lines. Using a completely rewritten interface, researchers can explore...
9.
Schmidt S, Akhave N, Knightly R, Reuben A, Vokes N, Zhang J, et al.
JCO Clin Cancer Inform
. 2022 Aug;
6:e2200040.
PMID: 35944232
Purpose: Advances in biological measurement technologies are enabling large-scale studies of patient cohorts across multiple omics platforms. Holistic analysis of these data can generate actionable insights for translational research and...
10.
Kim E, Novak L, Lin C, Colic M, Bertolet L, Gheorghe V, et al.
Genome Biol
. 2022 Jun;
23(1):140.
PMID: 35768873
Background: Coessentiality networks derived from CRISPR screens in cell lines provide a powerful framework for identifying functional modules in the cell and for inferring the roles of uncharacterized genes. However,...